In 2023, the treatment success rate for patients treated for multidrug-resistant tuberculosis in Brazil stood at 59%. The forecast from 2024 indicates a modest improvement, reaching 60% and maintaining a steady rate of 61% through 2028. The year-on-year variation reflects gradual progress—a 1.69% increase from 2023 to 2024, followed by stability in subsequent years. The 5-year Compound Annual Growth Rate (CAGR) shows an average annual increase of 0.67% from 2023 to 2028.
Future trends to watch for include advancements in treatment protocols and drug accessibility, which could further improve these rates. Monitoring policy changes and healthcare investments will also be critical in evaluating future success rates.
